HEADER HYDROLASE/HYDROLASE INHIBITOR 09-JUL-97 3FIV TITLE CRYSTAL STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED TITLE 2 WITH A SUBSTRATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: FELINE IMMUNODEFICIENCY VIRUS PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: FIV PR; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: ACE-ALN-VAL-LEU-ALA-GLU-ALN-NH2; COMPND 10 CHAIN: I, J; COMPND 11 SYNONYM: FIV PROTEASE INHIBITOR LP-149; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: FELINE IMMUNODEFICIENCY VIRUS; SOURCE 3 ORGANISM_TAXID: 11673; SOURCE 4 CELL_LINE: BL21; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21 (DE3) PLYSS; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: BL21; SOURCE 9 MOL_ID: 2; SOURCE 10 SYNTHETIC: YES KEYWDS ASPARTIC PROTEASE, RETROVIRAL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR C.SCHALK-HIHI,J.LUBKOWSKI,A.ZDANOV,A.WLODAWER,A.GUSTCHINA REVDAT 4 09-AUG-23 3FIV 1 REMARK SEQADV LINK REVDAT 3 13-JUL-11 3FIV 1 VERSN REVDAT 2 24-FEB-09 3FIV 1 VERSN REVDAT 1 12-NOV-97 3FIV 0 JRNL AUTH G.S.LACO,C.SCHALK-HIHI,J.LUBKOWSKI,G.MORRIS,A.ZDANOV, JRNL AUTH 2 A.OLSON,J.H.ELDER,A.WLODAWER,A.GUSTCHINA JRNL TITL CRYSTAL STRUCTURES OF THE INACTIVE D30N MUTANT OF FELINE JRNL TITL 2 IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH A SUBSTRATE JRNL TITL 3 AND AN INHIBITOR. JRNL REF BIOCHEMISTRY V. 36 10696 1997 JRNL REFN ISSN 0006-2960 JRNL PMID 9271500 JRNL DOI 10.1021/BI9707436 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH A.WLODAWER,A.GUSTCHINA,L.RESHETNIKOVA,J.LUBKOWSKI,A.ZDANOV, REMARK 1 AUTH 2 K.Y.HUI,E.L.ANGLETON,W.G.FARMERIE,M.M.GOODENOW,D.BHATT, REMARK 1 AUTH 3 L.ZHANG,B.M.DUNN REMARK 1 TITL STRUCTURE OF AN INHIBITOR COMPLEX OF THE PROTEINASE FROM REMARK 1 TITL 2 FELINE IMMUNODEFICIENCY VIRUS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 480 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 2 REMARK 2 RESOLUTION. 1.85 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.85 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 3.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0010 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 89.5 REMARK 3 NUMBER OF REFLECTIONS : 15187 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING SET) : 0.172 REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.85 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.93 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1307 REMARK 3 BIN R VALUE (WORKING SET) : 0.3110 REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1900 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 10 REMARK 3 SOLVENT ATOMS : 148 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.014 REMARK 3 BOND ANGLES (DEGREES) : 1.820 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 27.60 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.520 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 3.138 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 3.304 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 3.138 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.304 ; 2.500 REMARK 3 REMARK 3 NCS MODEL : RESTRAINTS REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : 0.005 ; 1000.0 REMARK 3 GROUP 1 B-FACTOR (A**2) : 1.35 ; 0.5 REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : TOPH19.PEP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HUBER AND ENGH PARAMETERS WERE USED IN REMARK 3 THE REFINEMENT. FOR NON-STANDARD RESIDUES (CYO, ALN, NAM, ACE, REMARK 3 SO4) LIBRARIES BASED ON EXISTING PARAMETERS WERE CREATED BY REMARK 3 SIMILARITY. THE X-RAY DATA ARE COMPATIBLE WITH THE SPACE GROUP REMARK 3 P31 2 1. THE LOWER SYMMETRY SPACE GROUP WAS UTILIZED IN REMARK 3 REFINEMENT FOR TECHNICAL REASONS. THE CHAINS A AND B (AND I AND REMARK 3 J) ARE THUS RELATED BY NON-CRYSTALLOGRAPHIC SYMMETRY, EQUIVALENT REMARK 3 TO TWO-FOLD AXIS DIFFERENTIATING THE TWO SPACE GROUPS. THE Z REMARK 3 VALUE IS GIVEN ON THE ASSUMPTION OF IDENTITY OF CHAINS A AND B. REMARK 4 REMARK 4 3FIV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000178964. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 23-APR-96 REMARK 200 TEMPERATURE (KELVIN) : 293 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : ENRAF-NONIUS FR591 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI FILTER REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MACSCIENCE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 40465 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 87.2 REMARK 200 DATA REDUNDANCY : 2.320 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.09100 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 16.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.83 REMARK 200 COMPLETENESS FOR SHELL (%) : 60.8 REMARK 200 DATA REDUNDANCY IN SHELL : 1.65 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.42000 REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.590 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR 3.1 REMARK 200 STARTING MODEL: PDB ENTRY 1FIV REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 37.61 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.05 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PROTEIN WAS CRYSTALLIZED FROM 2.0 M REMARK 280 AMMONIUM SULFATE, 0.1 M SODIUM ACETATE, PH=5.6. PROTEIN REMARK 280 CONCENTRATION, 5.0 MG/ML. CRYSTALLIZATION METHOD: HANGING DROP REMARK 280 VAPOR DIFFUSION, PH 5.6 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 24.84333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 49.68667 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, I, J REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE INHIBITOR ACE-ALN-VAL-LEU-ALA-GLU-ALN-NH2 IS DISORDERED. IT REMARK 400 APPEARS IN TWO ORIENTATIONS (CHAINS I AND J) THAT ARE RELATED BY REMARK 400 NON-CRYSTALLOGRAPHIC SYMMETRY. THE OCCUPANCY OF EACH ORIENTATION IS REMARK 400 1/2. REMARK 400 REMARK 400 THE N-ACETYL-3-(NAPHTHALEN-1-YL)-L-ALANYL-L-VALYL-L-LEUCYL-L-ALANYL- REMARK 400 L-ALPHA-GLUTAMYL-3-NAPHTHALEN-1-YL- L-ALANINAMIDE IS PEPTIDE-LIKE, REMARK 400 A MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: N-ACETYL-3-(NAPHTHALEN-1-YL)-L-ALANYL-L-VALYL-L-LEUCYL-L- REMARK 400 ALANYL-L-ALPHA-GLUTAMYL-3-NAPHTHALEN-1-YL- L-ALANINAMIDE REMARK 400 CHAIN: I, J REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 TYR A 1 REMARK 465 ASN A 2 REMARK 465 LYS A 3 REMARK 465 VAL A 4 REMARK 465 GLY A 5 REMARK 465 TYR B 1 REMARK 465 ASN B 2 REMARK 465 LYS B 3 REMARK 465 VAL B 4 REMARK 465 GLY B 5 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 78 CG CD OE1 OE2 REMARK 470 GLU B 78 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 46 -119.55 45.04 REMARK 500 LYS B 46 -119.69 44.95 REMARK 500 LEU I 204 47.41 -75.08 REMARK 500 LEU J 204 47.54 -75.34 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN I OF ACE-ALN-VAL-LEU-ALA REMARK 800 -GLU-ALN-NH2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN J OF ACE-ALN-VAL-LEU-ALA REMARK 800 -GLU-ALN-NH2 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2FIV RELATED DB: PDB DBREF 3FIV A 1 116 UNP P16088 POL_FIVPE 39 154 DBREF 3FIV B 1 116 UNP P16088 POL_FIVPE 39 154 DBREF 3FIV I 201 208 PDB 3FIV 3FIV 201 208 DBREF 3FIV J 201 208 PDB 3FIV 3FIV 201 208 SEQADV 3FIV ASN A 30 UNP P16088 ASP 68 ENGINEERED MUTATION SEQADV 3FIV ASN B 30 UNP P16088 ASP 68 ENGINEERED MUTATION SEQRES 1 A 116 TYR ASN LYS VAL GLY THR THR THR THR LEU GLU LYS ARG SEQRES 2 A 116 PRO GLU ILE LEU ILE PHE VAL ASN GLY TYR PRO ILE LYS SEQRES 3 A 116 PHE LEU LEU ASN THR GLY ALA ASP ILE THR ILE LEU ASN SEQRES 4 A 116 ARG ARG ASP PHE GLN VAL LYS ASN SER ILE GLU ASN GLY SEQRES 5 A 116 ARG GLN ASN MET ILE GLY VAL GLY GLY GLY LYS ARG GLY SEQRES 6 A 116 THR ASN TYR ILE ASN VAL HIS LEU GLU ILE ARG ASP GLU SEQRES 7 A 116 ASN TYR LYS THR GLN CSD ILE PHE GLY ASN VAL CYS VAL SEQRES 8 A 116 LEU GLU ASP ASN SER LEU ILE GLN PRO LEU LEU GLY ARG SEQRES 9 A 116 ASP ASN MET ILE LYS PHE ASN ILE ARG LEU VAL MET SEQRES 1 B 116 TYR ASN LYS VAL GLY THR THR THR THR LEU GLU LYS ARG SEQRES 2 B 116 PRO GLU ILE LEU ILE PHE VAL ASN GLY TYR PRO ILE LYS SEQRES 3 B 116 PHE LEU LEU ASN THR GLY ALA ASP ILE THR ILE LEU ASN SEQRES 4 B 116 ARG ARG ASP PHE GLN VAL LYS ASN SER ILE GLU ASN GLY SEQRES 5 B 116 ARG GLN ASN MET ILE GLY VAL GLY GLY GLY LYS ARG GLY SEQRES 6 B 116 THR ASN TYR ILE ASN VAL HIS LEU GLU ILE ARG ASP GLU SEQRES 7 B 116 ASN TYR LYS THR GLN CSD ILE PHE GLY ASN VAL CYS VAL SEQRES 8 B 116 LEU GLU ASP ASN SER LEU ILE GLN PRO LEU LEU GLY ARG SEQRES 9 B 116 ASP ASN MET ILE LYS PHE ASN ILE ARG LEU VAL MET SEQRES 1 I 8 ACE ALN VAL LEU ALA GLU ALN NH2 SEQRES 1 J 8 ACE ALN VAL LEU ALA GLU ALN NH2 MODRES 3FIV CSD A 84 CYS 3-SULFINOALANINE MODRES 3FIV CSD B 84 CYS 3-SULFINOALANINE MODRES 3FIV ALN I 202 ALA NAPHTHALEN-2-YL-3-ALANINE MODRES 3FIV ALN I 207 ALA NAPHTHALEN-2-YL-3-ALANINE MODRES 3FIV ALN J 202 ALA NAPHTHALEN-2-YL-3-ALANINE MODRES 3FIV ALN J 207 ALA NAPHTHALEN-2-YL-3-ALANINE HET CSD A 84 8 HET CSD B 84 8 HET ACE I 201 3 HET ALN I 202 15 HET ALN I 207 15 HET NH2 I 208 1 HET ACE J 201 3 HET ALN J 202 15 HET ALN J 207 15 HET NH2 J 208 1 HET SO4 A 501 5 HET SO4 B 502 5 HETNAM CSD 3-SULFINOALANINE HETNAM ACE ACETYL GROUP HETNAM ALN NAPHTHALEN-2-YL-3-ALANINE HETNAM NH2 AMINO GROUP HETNAM SO4 SULFATE ION HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE FORMUL 1 CSD 2(C3 H7 N O4 S) FORMUL 3 ACE 2(C2 H4 O) FORMUL 3 ALN 4(C13 H13 N O2) FORMUL 3 NH2 2(H2 N) FORMUL 5 SO4 2(O4 S 2-) FORMUL 7 HOH *148(H2 O) HELIX 1 1 ARG A 40 ASP A 42 5 3 HELIX 2 2 ARG A 104 LYS A 109 1 6 HELIX 3 3 ARG B 40 ASP B 42 5 3 HELIX 4 4 ARG B 104 PHE B 110 1 7 SHEET 1 A 4 LEU A 73 ILE A 75 0 SHEET 2 A 4 GLU A 15 VAL A 20 -1 N PHE A 19 O GLU A 74 SHEET 3 A 4 TYR A 23 LEU A 29 -1 N PHE A 27 O ILE A 16 SHEET 4 A 4 PRO A 100 LEU A 102 1 N PRO A 100 O LEU A 28 SHEET 1 B 4 ILE A 37 ASN A 39 0 SHEET 2 B 4 VAL A 89 LEU A 92 1 N CYS A 90 O LEU A 38 SHEET 3 B 4 GLY A 62 TYR A 68 -1 N TYR A 68 O VAL A 89 SHEET 4 B 4 ARG A 53 ILE A 57 -1 N MET A 56 O LYS A 63 SHEET 1 C 4 LEU B 73 ILE B 75 0 SHEET 2 C 4 GLU B 15 VAL B 20 -1 N PHE B 19 O GLU B 74 SHEET 3 C 4 TYR B 23 LEU B 29 -1 N PHE B 27 O ILE B 16 SHEET 4 C 4 PRO B 100 LEU B 102 1 N PRO B 100 O LEU B 28 SHEET 1 D 4 ILE B 37 ASN B 39 0 SHEET 2 D 4 VAL B 89 LEU B 92 1 N CYS B 90 O LEU B 38 SHEET 3 D 4 GLY B 62 TYR B 68 -1 N TYR B 68 O VAL B 89 SHEET 4 D 4 ARG B 53 ILE B 57 -1 N MET B 56 O LYS B 63 LINK C GLN A 83 N CSD A 84 1555 1555 1.32 LINK C CSD A 84 N ILE A 85 1555 1555 1.33 LINK C GLN B 83 N CSD B 84 1555 1555 1.32 LINK C CSD B 84 N ILE B 85 1555 1555 1.33 LINK C ACE I 201 N ALN I 202 1555 1555 1.32 LINK C ALN I 202 N VAL I 203 1555 1555 1.33 LINK C GLU I 206 N ALN I 207 1555 1555 1.32 LINK C ALN I 207 N NH2 I 208 1555 1555 1.33 LINK C ACE J 201 N ALN J 202 1555 1555 1.32 LINK C ALN J 202 N VAL J 203 1555 1555 1.33 LINK C GLU J 206 N ALN J 207 1555 1555 1.32 LINK C ALN J 207 N NH2 J 208 1555 1555 1.33 SITE 1 AC1 7 TYR A 23 LYS A 46 ARG A 104 HOH A 336 SITE 2 AC1 7 LYS B 12 ARG B 13 HOH B 440 SITE 1 AC2 7 LYS A 12 ARG A 13 HOH A 340 TYR B 23 SITE 2 AC2 7 LYS B 46 ARG B 104 HOH B 436 SITE 1 AC3 29 ARG A 13 PHE A 19 GLY A 22 LEU A 28 SITE 2 AC3 29 ASN A 30 GLY A 32 ALA A 33 ASP A 34 SITE 3 AC3 29 MET A 56 ILE A 57 ILE A 98 HOH A 301 SITE 4 AC3 29 HOH A 401 ARG B 13 PRO B 24 LEU B 28 SITE 5 AC3 29 ASN B 30 GLY B 32 ASP B 34 ILE B 35 SITE 6 AC3 29 MET B 56 ILE B 57 GLY B 58 VAL B 59 SITE 7 AC3 29 ILE B 98 GLN B 99 LEU B 101 HOH I 421 SITE 8 AC3 29 HOH J 321 SITE 1 AC4 28 ARG A 13 PRO A 24 LEU A 28 ASN A 30 SITE 2 AC4 28 GLY A 32 ASP A 34 ILE A 35 MET A 56 SITE 3 AC4 28 ILE A 57 GLY A 58 VAL A 59 ILE A 98 SITE 4 AC4 28 GLN A 99 LEU A 101 HOH A 301 HOH A 401 SITE 5 AC4 28 ARG B 13 PHE B 19 GLY B 22 LEU B 28 SITE 6 AC4 28 GLY B 32 ALA B 33 ASP B 34 MET B 56 SITE 7 AC4 28 ILE B 57 ILE B 98 HOH I 421 HOH J 321 CRYST1 50.890 50.890 74.530 90.00 90.00 120.00 P 31 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019650 0.011345 0.000000 0.00000 SCALE2 0.000000 0.022690 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013417 0.00000